

From: [Lindsay, Claire \(DPH\)](#)
To: [BOS-Supervisors](#)
Cc: [BOS-Legislative Aides](#); [Somera, Alisa \(BOS\)](#); [Wong, Linda \(BOS\)](#); [Patil, Sneha \(DPH\)](#); [Molloy, Delia \(DPH - Contractor\)](#); [Liu, Albert \(DPH\)](#); [Wong, Greg \(DPH\)](#); [Fleisher, Arielle \(DPH\)](#)
Subject: 5/4 BOS: DPH Retroactive Item
Date: Friday, April 30, 2021 2:38:45 PM

Hello Honorable Members of the Board of Supervisors:

The Department of Public Health (DPH) will request approval for one (1) retroactive item at the May 4th Full Board of Supervisors meeting. We would like to provide you with background information and reason for retroactivity prior to the meeting. Please see below for a brief description of the item and our DPH representatives whom you may contact directly should you have any questions.

Agenda item #15 – File no. 210359 - Accept and Expend Grant - Retroactive - National Institute of Allergy and Infectious Diseases - Research Triangle Institute International - AMBER Statement of Work - Department of Public Health - \$113,581 - Resolution retroactively authorizing the Department of Public Health to accept and expend a grant in the amount of \$113,581 from the National Institute of Allergy and Infectious Diseases through Research Triangle Institute International for participation in a program, entitled “AMBER Statement of Work - San Francisco Department of Public Health,” for the period of December 15, 2020, through July 31, 2025.

- **Program Description:** The scope of work for this grant is to conduct iterative socio-behavioral research with target end-user populations in the United States. The goal of the research is to inform the development of a biodegradable implant that can deliver sustained release of pre-exposure prophylaxis (PrEP), which is an HIV prevention medication. This biodegradable implant could provide long-term protection from HIV for up to a year. The rationale for this study is that while oral PrEP is available in the form of pills, adherence can be difficult for taking a daily medication. This implant may reduce some of these barriers. DPH will focus its socio-behavioral effects on predominantly minority, sexually active, cis-men who have sex with men (MSM) as well as transgender women (TGW). Attributes and preferences of the implant by end-users will inform the early stage development and therefor support successful uptake by eventual users. Dr. Albert Liu will lead the work to evaluate preferred user characteristics of the AMBER implant in SF and the East Bay. This grant does not require an ASO amendment and partially reimburses the department for one existing position.
- **Reason for Retroactive Approval:** We are respectfully requesting retroactive approval to accept and expend these funds as DPH received the letter of funding allocation on February 5, 2021 for a program start date of December 15, 2020.
- **DPH Representatives:**
 - Delia Molloy, MA | Deputy Director, Bridge HIV | San Francisco Department of Public Health | delia.molloy@sfdph.org
 - Albert Liu, MD, MPH | Clinical Research Director, Bridge HIV | San Francisco Department of Public Health | albert.liu@sfdph.org

Thank you for your time and consideration,
Claire

-

Claire Lindsay, MPH

Senior Health Program Planner | Office of Policy and Planning

San Francisco Department of Public Health

claire.lindsay@sfdph.org | desk: 415-554-2667 | mobile: 831-239-1094